Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000821434 | SCV000962189 | uncertain significance | Bardet-Biedl syndrome 3; Retinitis pigmentosa 55 | 2024-10-08 | criteria provided, single submitter | clinical testing | This sequence change replaces isoleucine, which is neutral and non-polar, with asparagine, which is neutral and polar, at codon 47 of the ARL6 protein (p.Ile47Asn). This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with ARL6-related conditions. ClinVar contains an entry for this variant (Variation ID: 663541). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Fulgent Genetics, |
RCV005036220 | SCV005659814 | uncertain significance | Bardet-Biedl syndrome 1; Bardet-Biedl syndrome 3; Retinitis pigmentosa 55 | 2024-03-05 | criteria provided, single submitter | clinical testing | |
Prevention |
RCV003918280 | SCV004732709 | uncertain significance | ARL6-related disorder | 2023-12-26 | no assertion criteria provided | clinical testing | The ARL6 c.140T>A variant is predicted to result in the amino acid substitution p.Ile47Asn. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.0054% of alleles in individuals of East Asian descent in gnomAD (1 allele; http://gnomad.broadinstitute.org/variant/3-97499019-T-A). At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |